Why Do Some People Say ‘It’s Legal’ but Still Can’t Get It on the NHS?

It’s a question that confuses many healthcare consumers in the UK: certain treatments and medicines are described as “legal” and “prescribing lawful,” yet they remain unavailable or restricted on the NHS. What’s behind this disconnect between legality and real-world NHS access? The answer lies in the complex interplay of NHS funding constraints, clinical guidelines, specialist prescribing regulations, and the growing role of private providers, especially in areas like video consultations and remote prescribing.

Legality vs Real-World Access: Understanding the Gap

When people say a treatment is lawful or “it’s legal,” they usually mean that the medicine or service has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and can be prescribed within the UK’s regulatory framework. However, legal status does not automatically guarantee NHS availability or funding. This is because NHS England, Wales, Scotland, and Northern Ireland each make independent decisions about which treatments to commission and reimburse based on clinical evidence, cost-effectiveness, and local health priorities.

In practice, this means different scenarios can occur:

• A treatment authorised for use but considered to have limited indications by NHS commissioners
• A medicine that can legally be prescribed but is not routinely funded on the NHS due to cost constraints
• Access restricted only to certain patient groups or under specialist care pathways

These distinctions create confusion for patients who hear it is “legal” but then find they cannot get it on the NHS without a specialist referral or at all.

The NHS Funding Gap and the Growth of the Private Market

One key reason for this availability gap is the NHS funding gap. Despite the NHS’s universal healthcare mandate, budget limitations mean not every approved medicine or service can be provided free at the point of use. The NHS prioritises treatments that provide the most health benefit per pound spent, often guided by bodies such as the National Institute for Health and Care Excellence (NICE).

When treatments fall outside these priorities or are new and expensive, many patients turn to the private sector. This is especially true for consultations and prescriptions involving newer or less widely used medicines. The rise of private clinics offering video consultations and remote prescribing demonstrates how market demand fills gaps left by the NHS, but often at a financial cost to patients.

Who Can Prescribe? The Role of Specialist Registers and Regulations

Prescribing lawful is not solely a question of legality; it also depends on who is qualified and authorised to prescribe certain medicines. In the UK, doctors must be registered with the General Medical Council (GMC) to prescribe prescriptions legally.

More crucially, for certain complex or limited indication treatments, the GMC Specialist Register status can be a requirement for prescribing. This means the prescriber must have particular specialist qualifications or expertise associated with the drug’s approved uses.

For example, some cancer drugs, psychiatric medications, or advanced therapies require specialist oversight. This ensures patient safety, appropriate monitoring, and adherence to clinical protocols. General practitioners (GPs) may not initiate or continue prescriptions for these drugs without specialist input. This is another reason some patients cannot access legally prescribed medicines via the NHS unless referred to the appropriate specialist.

Video Consultations and Remote Prescribing: Regulation and CQC Oversight in England

The expansion of video consultations and remote prescribing has transformed private healthcare access, allowing patients to consult clinicians online and receive prescriptions remotely. However, these services are regulated, especially in England.

Since April 2023, clinics that offer remote prescribing via online consultations must declare this activity to the Care Quality Commission (CQC). The CQC monitors these providers to ensure they meet safety, governance, and clinical standards.

Despite these regulations, transparency around consultation and prescription pricing remains an issue. Many private providers fail to clearly state their consultation fees or prescription charges upfront, making it difficult for patients to make informed choices. Unlike the NHS, where costs are clear or covered, private market pricing may include separate fees for consultations and again for medicines, especially for controlled substances or specialist drugs.

Common Mistake: Lack of Transparent Pricing

A widespread problem among private clinics offering remote and video consultations is vague or missing price information. Patients often encounter websites that advertise treatment availability but provide no clear consultation fees or prescription costs.

This lack of transparency is problematic because:

• Patients cannot budget or decide if a service is financially viable
• There may be additional charges for follow-up consultations or prescription renewals
• Hidden costs undermine trust and informed consent

Best practice is for private providers to publish full pricing including the cost of consultation, any follow-up consultations, and the price of medicines dispensed or prescribed remotely. Ideally, this pricing should be presented before booking the consultation.

Summary Checklist: Why “It’s Legal” Doesn’t Always Mean NHS Access

Factor Explanation Prescribing Lawful Medicine approved by MHRA and can be prescribed legally by qualified professionals NHS Funding Gap Budget constraints prevent all approved treatments from being available free on the NHS Limited Indications NHS restricts funding to specific patient groups or specialist pathways based on clinical evidence Who Can Prescribe? Often requires GMC Specialist Register physicians for complex or restricted drugs Regulation in England Remote prescribing and video consultations must be declared to CQC for oversight Pricing Transparency Private providers should clearly state consultation and prescription prices upfront

Conclusion

Understanding why a medicine or treatment can Visit this link be “legal” but unavailable on the NHS requires separating legal status, funding realities, clinical governance, and regulatory oversight. The NHS must balance cost-effectiveness, prioritisation, and specialist requirements — all of which shape real-world access. Meanwhile, private providers with video consultations and remote prescribing offer alternative routes but must operate transparently, especially regarding pricing and compliance with CQC requirements in England.

For patients navigating these complexities, the key is to ask clear questions: Is my prescriber properly qualified? Is this treatment routinely funded on the NHS? What are the full costs involved Additional resources if I choose private care? By clarifying these points, patients can make informed decisions informed by legality but grounded in practical access.